Epcoritamab Drug Asset Due Diligence Report 2026

This Epcoritamab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

174

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Epcoritamab can convert its Bispecific T-cell Engager (BiTE) profile and CD20 x CD3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Epcoritamab (query alias: Epcoritamab)
Modality / target	Bispecific T-cell Engager (BiTE); CD20 x CD3; CD20 inhibitors, CD3 stimulants
Highest global status	Approved
Originator	Genmab A/S
Active developers	AbbVie, Inc., Genmab A/S, Genmab, Inc.

The MCP disease footprint includes Large B-cell lymphoma, Recurrent Grade 3b Follicular Lymphoma, Mediastinal large B-cell lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600123526	Phase 4	Not yet recruiting	45	Progression free survival, PFS
NCT07662928	Phase 2	Not yet recruiting	43	Proportion of participants who complete at least Cycle 3 among 10 participants (Feasibility)
NCT07588698	Phase 2	Not yet recruiting	20	Cytokine Release Syndrome (CRS) Rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial

Phase 2; n=108; evaluation: Positive. Reported fields: Adverse Event: hypertension = seven [11%] ; Adverse Event: hypertension = seven [11%] ; Adverse Event: hypertension = seven [11%]

Early toxicity and temporal mortality patterns following bispecific T-cell engager therapy: A real-world multicenter analysis.

Not Applicable; n=3642; evaluation: Positive. Reported fields: all-cause mortality = 0.7 %

Real-world experience with management of CRS and ICANS following CD3xCD20 bispecific antibody therapy.

Not Applicable; n=63; evaluation: Positive. Reported fields: -; CRS(Grade 1) = 18.0 Pts ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Epcoritamab addresses Large B-cell lymphoma, Recurrent Grade 3b Follicular Lymphoma, Mediastinal large B-cell lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific T-cell Engager (BiTE)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-06-10	Genmab and AbbVie Announce Broad Oncology Collaboration	Phase 2	US$750.0M upfront; US$3,150.0M milestones; US$3,900.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Cytokine-release syndrome, neurotoxicity, and infection
Durability after deep B-cell or plasma-cell depletion
Dose-step-up logistics, manufacturing, and outpatient feasibility

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO